Accepted for/Published in: JMIR Research Protocols
Date Submitted: Feb 16, 2026
Date Accepted: Mar 30, 2026
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Digital Cognitive Behavioral Therapy for Insomnia versus Sleep Hygiene Education for Prevention of Perinatal Depression: Protocol for a Randomized Clinical Trial
ABSTRACT
Background:
Insomnia during pregnancy is a modifiable risk factor for depression. Research in non-pregnant populations and preliminary findings in a pregnant population suggest that targeting insomnia with digital cognitive behavioral therapy for insomnia (CBT-I) may prevent depression.
Objective:
This study aims to evaluate the efficacy of digital CBT-I for the prevention of depression through 12 months postpartum compared with a credible, clinically relevant comparator intervention, sleep hygiene education (SHE). This project will also provide valuable information about how and for whom CBT-I prevents perinatal depression.
Methods:
The Perinatal Research for Improving Sleep and Mental health (PRISM) Study is a fully remote, two-arm parallel-group randomized controlled trial designed to test the superiority of digital CBT-I versus SHE for the prevention of perinatal depression. We aimed to randomize a target sample of at least 443 pregnant participants with insomnia disorder to digital CBT-I or SHE at a 1:1 ratio. Participants randomized to digital CBT-I received SleepioRx (Big Health, Inc), which uses sleep consolidation, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene education in six interactive modules (5-15 minutes each). Participants randomized to SHE received information about sleep hygiene, the impact of sleep on performance, healthy sleep habits, lifestyle influences on sleep, and creating a sleep-friendly bedroom in six weekly digital handouts. Data are collected at baseline, 5 weeks after randomization, 10 weeks after randomization, 36 weeks’ gestation, and 3, 6, 9, and 12 months postpartum. The primary outcome is depression incidence, measured using the Structured Clinical Interview for DSM-5 Disorders. Other outcome measures include the Edinburgh Postnatal Depression Scale, Patient Health Questionnaire-9, Columbia Suicide Severity Rating Scale, Generalized Anxiety Disorder Scale, and a birth outcomes questionnaire. Mediator measures include the Insomnia Severity Index, Consensus Sleep Diary, Structured Clinical Interview for DSM-5 Sleep Disorders, Perseverative Thinking Questionnaire, Dysfunctional Beliefs about Sleep Scale, Pre-sleep Arousal Scale, and Difficulties in Emotion Regulation-Short Form.
Results:
Data collection began in November 2022 and is projected to end December 2026.
Conclusions:
If study hypotheses are supported, then this project will provide a new, scalable approach for preventing perinatal depression. Clinical Trial: ClinicalTrials.gov NCT05596318; https://clinicaltrials.gov/study/NCT05596318
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.